Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;32(1):e22185.
doi: 10.1002/jcla.22185. Epub 2017 Feb 26.

Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer

Jin Wang  1   2 , Jinglei Qu  1   2 , Zhi Li  1   2 , Xiaofang Che  1   2 , Jing Liu  1   2 , Yuee Teng  1   2 , Bo Jin  1   2 , Mingfang Zhao  1   2 , Yunpeng Liu  1   2 , Xiujuan Qu  1   2
Affiliations

Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer

Jin Wang et al. J Clin Lab Anal. 2018 Jan.

Abstract

Background: Several studies have shown that platelet-to-lymphocyte ratio (PLR) is a prognostic factor for various cancers. However, there is no study about the role of PLR in predicting response to first-line chemotherapy of metastatic gastric cancer. Therefore, this study aimed to establish whether PLR is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer.

Methods: We enrolled 273 patients diagnosed with metastatic gastric cancer. The best cut-off value of PLR to predict chemotherapeutic response was chosen by receiver operating characteristic (ROC) curve analysis. Prognostic significance was determined using the log-rank test and multivariate Cox regression analysis.

Results: Based on the cut-off value of PLR, patients were divided into a low PLR group and high PLR group. In logistic regression analysis, the low PLR group had a significantly higher disease control rate than the high PLR group had (91.3 vs 76.1%, P=.002), and PLR was an independent risk factor for response to first-line chemotherapy (odds ratio [OR]: 3.256; 95% confidence interval [CI]: 1.521-6.969; P=.002). The low PLR group had significantly longer overall survival (OS) than the high PLR group had (13.4 vs 9.2 months; P=.020). Multivariate survival analysis showed that PLR was significantly associated with OS [hazard ratio (HR): 1.002; 95% CI: 1.000-1.003; P=.020].

Conclusions: Pre-treatment PLR is associated with the response rate to first-line chemotherapy and survival outcomes in patients with metastatic gastric cancer.

Keywords: chemotherapy; gastric cancer; platelet-to-lymphocyte ratio; tumor response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Receiver operating characteristic curve for the platelet‐to‐lymphocyte ratio and the response to first‐line chemotherapy for patients with metastatic advanced gastric cancer
Figure 2
Figure 2
Kaplan‐Meier survival curves of all patients (high and low platelet‐to‐lymphocyte ratio group patients)
Figure 3
Figure 3
Kaplan‐Meier curves for the overall survival in patients who received two larger regimen subgroups. (A) Patients who received oxaliplatin‐based regimen. (B) Kaplan‐Meier survival curves in patients who received taxane‐based regimen
Figure 4
Figure 4
Kaplan‐Meier survival curves in all the patients using different cutoff values of platelet‐to‐lymphocyte ratio (PLR). (A) the overall survival of patients using dichotomized cutoff value for PLR. (B) the overall survival of patients using triple subsets cutoffs for PLR
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635–1649. - PMC - PubMed
    1. Koizumi W, Narahara H, Hara T, et al. S‐1 plus cisplatin versus S‐1 alone for first‐line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221. - PubMed
    1. Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S‐1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140:319–328. - PMC - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet. 2010;376:687–697. - PubMed

MeSH terms

Substances